Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107964 · ClinicalTrials.gov registry record · NA
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
A NA study of Dry Eye Syndrome, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT01107964: Completed NA study of Dry Eye Syndrome, sponsored by Milton S. Hershey Medical Center.
NCT01107964 is a NA study of Dry Eye Syndrome that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 27 participants, below the 162-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01107964, a NA study of Dry Eye Syndrome, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluorescein tear break-up time) when compared to administration of placebo.
Primary Outcome
The Ocular Surface Disease Index Score is a validated, scored questionnaire that measures subjective symptoms of dry eye. Possible scores range from 0 (no symptoms of dry eye) to 100 (severest symptoms of dry eye). Change = (Day 45 score - Baseline score)
Conditions Studied
Interventions
- DRUG Oral Omega-3-acid ethyl esters
- DRUG Placebo corn oil capsule
Study Locations (1)
Pennsylvania
- Penn State Hershey Eye Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-06-15 |
| Phase | NA |
What the finished NCT01107964 record still lists
NCT01107964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 162-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Dry Eye Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Oral Omega-3-acid ethyl esters is the first listed.
NCT01107964 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01107964 about?
NCT01107964 is a clinical study titled "Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome". The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluore...
What is the current status of trial NCT01107964?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2010-07. Estimated completion is 2015-06-15.
What conditions does trial NCT01107964 study?
This clinical trial studies the following conditions: Dry Eye Syndrome.
What interventions are being tested in trial NCT01107964?
The interventions under investigation include: Oral Omega-3-acid ethyl esters (DRUG), Placebo corn oil capsule (DRUG).
Who is sponsoring clinical trial NCT01107964?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01107964 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01107964's enrollment target sits among peer trials
27 9th of 10 higher than 2 of 10 other Dry Eye Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
COMPLETED · NA
-
The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
COMPLETED · NA
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
RECRUITING · Phase 1
-
Study of SkQ1 as Treatment for Dry-eye Syndrome
COMPLETED · Phase 3
-
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
COMPLETED · Phase 2
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia